Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

NewsGuard 100/100 Score
Nov 18 2009

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population.

A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study (http://www.clinicaltrials.gov) under an IND recently placed into effect by the FDA.

Source:

Albireo

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Chronic disease increases the odds of hospitalization from heat exposure, study finds
Researchers identify key molecular alterations from endurance exercise that could combat chronic diseases
Are your snacks deadly? New study reveals how ultra-processed foods lead to chronic disease outcomes
Ultra-processed foods raise chronic kidney disease risk, study shows
Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support
Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support
Chronic underhydration linked to major health risks, study finds
Hydrogel with built-in antibiofilm and antioxidative functions promotes faster healing of infected chronic wounds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Higher dietary niacin intake linked to lower COPD risk, study finds